Cognition Therapeutics Reports Q2 2025 Net Loss of $6.7M, EPS Improves to $(0.11) from $(0.18)

Reuters
08/08
Cognition <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Net Loss of $6.7M, EPS Improves to $(0.11) from $(0.18)

Cognition Therapeutics Inc. has reported a net loss of $6.7 million for the second quarter ended June 30, 2025, compared to a net loss of $7.0 million for the same period in 2024. The company's cash, cash equivalents, and restricted cash equivalents were approximately $11.6 million as of June 30, 2025. Additionally, Cognition Therapeutics has $41.9 million in total obligated grant funds remaining from the National Institute of Aging. Research and development expenses for the quarter were $11.5 million, a slight decrease from $11.6 million in the comparable period of 2024, primarily due to reduced professional fees. General and administrative expenses also decreased to $2.5 million from $3.1 million in the previous year, driven mainly by reduced stock-based compensation expenses. The company highlighted significant progress in its clinical programs, including a productive end-of-phase 2 meeting with the FDA for its Alzheimer's disease program and the initiation of an expanded access program for people with dementia with Lewy bodies. Cognition also surpassed 50% enrollment in its Phase 2 'START' study of zervimesine for early Alzheimer's disease. These advancements emphasize the potential of zervimesine to slow the progression of age-related degenerative diseases. The company estimates that its current cash resources will fund operations and capital expenditures into the second quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cognition Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9508498-en) on August 07, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10